Jinxin Fertility Group Limited (abbrev. “Jinxin Fertility”) has disclosed the repurchase of 1.83 million ordinary shares on 9 November 2026 under its Hong Kong–listed buy-back programme.
Key Transaction Details • Volume repurchased: 1.83 million shares, equal to 0.07% of the company’s issued share capital (excluding treasury shares) prior to the transaction. • Price range: HKD 2.29–2.37 per share; volume-weighted average price approximately HKD 2.32. • Aggregate consideration: HKD 4.24 million, settled in cash. • Method: On-market repurchase via The Stock Exchange of Hong Kong.
Capital Structure Post-Repurchase (as at 9 November 2026) • Issued shares (ex-treasury): 2.63 billion, down from 2.63 billion on 6 November 2026. • Treasury shares: 78.48 million, up from 76.65 million. • Total issued shares (including treasury): unchanged at 2.71 billion.
Outstanding Cancellation Pipeline Since March 2026 the company has bought back 91.02 million shares for cancellation that were still awaiting cancellation as of 9 November 2026. These shares represent 3.47% of the issued share base at the date (25 June 2026) when shareholders approved the current 262.51 million-share buy-back mandate. The latest transaction lifts utilisation of that mandate to roughly 34.7%.
Issuance Moratorium In accordance with Hong Kong listing rules, Jinxin Fertility is restricted from issuing new shares or disposing of treasury shares until 9 December 2026.
Corporate Context Jinxin Fertility, incorporated in the Cayman Islands and listed on the Hong Kong Stock Exchange (stock code 01951), continues to employ share repurchases both for treasury and future cancellation, signalling an ongoing capital management initiative within the limits authorised by shareholders.
Comments